For the quarter ending 2025-09-30, SGMT has $128,401K in assets. $32,496K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 32,496 | 42,327 | ||
| Short-term marketable securities | 84,197 | 83,080 | ||
| Prepaid expenses and other current assets | 2,787 | 1,789 | ||
| Total current assets | 119,480 | 127,196 | ||
| Long-term marketable securities | 8,806 | 10,059 | ||
| Operating lease right-of-use assets | 115 | 152 | ||
| Total assets | 128,401 | 137,407 | ||
| Accounts payable | 4,243 | 1,921 | ||
| Accrued expenses and other current liabilities | 4,788 | 5,174 | ||
| Operating lease liabilities | 115 | 152 | ||
| Total current liabilities | 9,146 | 7,247 | ||
| Common stock-Common Class A | 3 | 3 | ||
| Common stock-Common Class B | 0 | 0 | ||
| Additional paid-in capital | 455,916 | 453,954 | ||
| Accumulated deficit | -336,781 | -323,873 | ||
| Accumulated other comprehensive income | 117 | 76 | ||
| Total stockholders' equity | 119,255 | 130,160 | ||
| Total liabilities and stockholders' equity | 128,401 | 137,407 | ||
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)